Huajian Medical and Chuangsheng Group Sign 1.50 billion US Dollar Innovative Drug Pipeline Asset RWA Tokenization Strategic Cooperation Agreement
2025-09-22 01:35:06
On September 22, the Hong Kong-listed company Huajian Medical announced that its company and its subsidiaries, ETHK Inc and ETHKHOLDINGSLIMITED, and Chuangsheng Group Pharmaceutical Co., Ltd. and its subsidiaries TranscentaOncologyInc. Signed a US $1.50 billion strategic cooperation agreement on potential innovative drug pipeline assets RWA tokenization related matters.
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
